Rapid Medical Diagnostic Kits Market, By Test Type (Blood glucose monitoring test kits, Pregnancy test kits, Infectious disease test kits, Coagulation monitoring test kits, Others), By Sample Type Blood tests, Urine tests, Saliva tests, Others), By End User (Hospitals and clinics, Home care settings, Diagnostic laboratories), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
The rapid medical diagnostic kits market size is expected to reach US$ 40.3 billion by 2030, from US$ 21.6 billion in 2023, at a CAGR of 9.3% during the forecast period. Rapid diagnostic tests (RDTs) are those tests that aim to diagnose the cause of a given infection with turnaround times significantly shorter than those provided by conventional ones.
Rapid Medical Diagnostic Kits Market Regional Insights:
North America is expected to be the largest market for rapid medical diagnostic kits market during the forecast period, accounting for over 47% of the market share in 2023. The growth of the market in North America is attributed to increasing product launches.
The Europe market is expected to be the second-largest market for rapid medical diagnostic kits market, accounting for over 27.3% of the market share in 2023. The growth of the market is attributed to increasing inorganic strategies by market players.
The Asia Pacific market is expected to be the fastest-growing market for rapid medical diagnostic kits market, with a CAGR of over 6.1% during the forecast period. The growth of the market in Asia Pacific is attributed to the increasing prevalence of hepatitis C in the region.
Figure 1. Global Rapid Medical Diagnostic Kits Market Share (%), by Region, 2023
Analysts’ Views on Global Rapid Medical Diagnostic Kits Market:
The rapid diagnostic kits market is expected to grow exponentially over the forecast period owing to the increasing incidence of infectious diseases globally. Moreover, increasing novel testing kits launch by the market players is expected to aid in the market growth over the forecast period.
Rapid Medical Diagnostic Kits Market Drivers:
Growing Prevalence of Infectious Diseases and Epidemiology: The global prevalence of infectious diseases and epidemiology is a major factor driving the growth of the global rapid medical diagnostic kits market. With the rise in communicable and vector-borne diseases worldwide in the past decade, primarily due to factors like climate change, globalization, and increased international travel and trade, there is increased urgency and a focus on faster diagnosis of such diseases. Rapid diagnostic kits play a crucial role in fighting infectious disease outbreaks by enabling immediate confirmatory diagnosis at the point of care. This is invaluable for both clinicians and public health officials to take quick actions in terms of appropriate treatment, contact tracing, surveillance, and outbreak management. For instance, during the ongoing COVID-19 pandemic, rapid antigen test kits that provide results within 30 minutes have been game-changing in scaling up testing capacities across countries. According to data by the World Health Organization, as of October 2021, about 920 million rapid antigen tests for COVID-19 had been distributed globally to low- and middle-income countries.
Faster Results of Rapid Test Kits: The demand for rapid medical diagnostic kits is growing rapidly across the globe owing to the increasing need for faster diagnostic results. Conventional diagnostic methods can often take days to provide results, thereby delaying the start of appropriate treatment. However, rapid diagnostic kits provide results within minutes or hours, allowing for swift medical intervention. This is proving crucial in various medical scenarios. The COVID-19 pandemic has further driven the need for rapid diagnostic testing. As the virus spread quickly worldwide, it became essential to identify infected individuals faster in order to curb transmission and prioritize treatment. Rapid antigen and antibody test kits played a pivotal role here by facilitating large-scale community screening and enabling the monitoring of prevalence in real-time. For example, the U.K. government conducted several national community testing surveys in 2021 and 2022, involving the distribution of hundreds of thousands of lateral flow antigen test kits to estimate infection levels. Rapid testing was crucial in making strategic decisions and assessing the impact of control measures in dealing with viral surges.
Rapid Medical Diagnostic Kits Market Opportunities:
New Product Launches: New product launches could present a major opportunity in the global rapid medical diagnostic kits market. With innovation happening at a rapid pace in medical diagnostics, companies are bringing novel solutions to market that can address public health challenges and help save lives. Rapid diagnostic kits, which can detect diseases accurately within a short span of time, have huge potential to transform healthcare worldwide. For instance, on July 12, 2021, Abbott, a medical device company, announced the launch of Panbio COVID-19 Antigen Self-Test for the detection of the SARS-CoV-2 virus in adults and children with or without symptoms.
Global Rapid Medical Diagnostic Kits Market Report Coverage
Report Coverage
Details
Base Year:
2022
Market Size in 2023:
US$ 21.6 Bn
Historical Data for:
2018 to 2021
Forecast Period:
2023 - 2030
Forecast Period 2023 to 2030 CAGR:
9.3%
2030 Value Projection:
US$ 40.3 Bn
Geographies covered:
North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
By Test Type: Blood glucose monitoring test kits, Pregnancy test kits, Infectious disease test kits, Coagulation monitoring test kits, Others
By Sample Type: Blood Test, Urine Test, Saliva Test, Others
By End User: Hospitals and clinics, Home care settings, Diagnostic laboratories
Companies covered:
Abbott Laboratories, Roche, Becton Dickson and company, Thermo Fisher Scientific, Quidel Corporation, bioMérieux SA, Meridian Bioscience, Inc., PerkinElmer, Inc., LumiraDx
Growth Drivers:
Growing Prevalence of Infectious Diseases And Epidemiology
Growing Demand for Multi-Disease Diagnostic Tests: The growing demand for multi-disease diagnostic tests is having a significant influence on the global rapid medical diagnostic kits market. Consumers are increasingly looking for tests that can simultaneously screen for multiple health conditions from a single sample. This allows for greater convenience and a more efficient testing process as compared to multiple individual tests. Rapid diagnostic kit manufacturers are recognizing this shifting trend and are developing new products accordingly. For example, companies like Abbott and Roche now offer rapid tests that can detect up to 4-5 major infectious diseases from a single sample. Their influenza, strep throat, and respiratory syncytial virus (RSV) panels can deliver results in 15-30 minutes from a single nasal swab. This saves patients from undergoing multiple tests and waiting for separate results. It also enables doctors to prescribe the right treatment faster. Moreover, the kits that test for multiple diseases require a smaller sample volume compared to individual tests, thereby providing an improved user experience.
Rapid Medical Diagnostic Kits Market Restraints:
Issues Regarding Accuracy and Reliability: One of the major factors restraining the growth of the global rapid medical diagnostic kits market is concerns around the accuracy and reliability of these tests. While rapid diagnostic kits offer the convenience of quick results, there are ongoing debates in the medical community regarding their performance as compared to laboratory-based diagnostic methods. Rapid tests are often less sensitive than laboratory tests, meaning they may show false negatives. According to a 2021 study conducted by the World Health Organization on COVID-19 antigen rapid diagnostic tests, the sensitivity of these tests ranged between 34-80% compared to RT-PCR tests. Several observational studies have also suggested that the accuracy of rapid antigen tests depends heavily on viral load and timing of infection. False negatives with rapid tests can undermine containment efforts and lead to unchecked community transmission. Accuracy issues have led to less than optimal adoption of rapid tests, even in situations where they could be immensely helpful, like in low- and middle-income countries. For example, according to a 2020 report by UNAIDS, while rapid HIV tests were widely available in many developing countries, concerns about reliability meant that people preferred visiting labs for confirmatory tests, undermining the potential of self-testing. This lack of full confidence in rapid testing technology is a primary reason several national HIV/AIDS programs still rely predominantly on laboratory-based testing. Moreover, if market players stats focusing on accuracy of the devices which is expected to aid in the market growth over the forecast period.
Recent Developments:
New product launches:
On February 23, 2023, Mylab Discovery Solutions, which offers rapid diagnostic kits, announced that it had expanded its portfolio of rapid tests for sexually transmitted diseases (STIs), namely HIV, HCV and Syphilis.
On October 12, 2022, Roche, a pharmaceutical company, announced the launch of SARS-CoV-2 rapid antigen tests for self-testing and professional use in countries accepting the CE Mark.
Acquisition and Partnerships:
On August 17, 2023, CrisprBits, a biotech startup, announced that is had formed a strategic collaboration with MolBio Diagnostics to launch CRISPR-based point-of-care tests.
Figure 2. Global Rapid Medical Diagnostic Kits Market Share (%), by Test Type, 2023
Top companies in Rapid Medical Diagnostic Kits Market:
Abbott Laboratories
Roche
Becton, Dickinson and Company
Thermo Fisher Scientific
Quidel Corporation
bioMérieux SA
Meridian Bioscience, Inc.
PerkinElmer, Inc.
LumiraDx
Definition: Rapid diagnostic tests (RDTs) are those tests that aim to diagnose the cause of a given infection with turnaround times significantly shorter than those provided by conventional ones.
Few Other Promising Reports in Pharmaceuticals Industry
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
The global Rapid Medical Diagnostic Kits Market size was valued at USD 21.6 billion in 2023 and is expected to reach USD 40.3 billion in 2030.
Issues regarding accuracy and reliability are expected to hinder market growth over the forecast period.
The growing prevalence of infectious diseases and epidemiology, faster results of rapid test kits are expected to propel market growth over the forecast period.
The leading segment is blood test in test type segment due to increasing product launches by the market players.
Abbott Laboratories, Roche, Becton Dickson and company, Thermo Fisher Scientific, Quidel Corporation, bioMérieux SA, Meridian Bioscience, Inc., PerkinElmer, Inc., LumiraDx
North America will lead the rapid medical diagnostic kits market.
The CAGR of the rapid medical diagnostic kits market is 9.3%
U.S.: 
U.K. : 
India : 
